Actueel
-
Gefitinib: Treatment for EGFR-Mutated Non-Small Cell Lung CancerLung cancer remains one of the most prevalent and deadly cancers worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. Among NSCLC patients, mutations in the epidermal growth factor receptor (EGFR) gene have been identified as a key driver of tumor growth. Gefitinib, an oral tyrosine kinase inhibitor (TKI), has emerged as a revolutionary treatment for...0 Reacties 0 aandelen 45 Views 0 voorbeeldPlease log in to like, share and comment!
-
0 Reacties 0 aandelen 57 Views 0 voorbeeld
Meer blogs